Ionis Pharmaceuticals
IONS
354 hedge funds and large institutions have $5.61B invested in Ionis Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 58 funds opening new positions, 119 increasing their positions, 120 reducing their positions, and 50 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
16% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 50
1.72% more ownership
Funds ownership: 99.9% → 101.62% (+1.7%)
0% more funds holding
Funds holding: 353 → 354 (+1)
1% less repeat investments, than reductions
Existing positions increased: 119 | Existing positions reduced: 120
11% less capital invested
Capital invested by funds: $6.3B → $5.61B (-$692M)
15% less call options, than puts
Call options by funds: $26.1M | Put options by funds: $30.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$136M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$66M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$65.4M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$53M |
| 5 |
BlackRock
New York
|
+$31.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$74.3M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$58.2M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$41.4M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$30M |
| 5 |
Pictet Asset Management
Carouge,
Switzerland
|
-$25.5M |
IONS Hedge Fund Activity: Q4 2024 in Review
354 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q4 2024, worth a combined $5.61B — down 11% from $6.3B a quarter earlier.
Buyers outnumbered sellers: 58 funds opened new IONS positions and 50 closed out — a net gain of 8 holders — while 119 added to existing stakes and 120 trimmed.
The largest buyer was Capital World Investors, adding an estimated $136M. The largest seller was Artisan Partners, cutting an estimated $74.3M.
- 354 institutional investors held Ionis Pharmaceuticals (IONS) as of Q4 2024, up from 353 in Q3 2024.
- Funds reported $5.61B of Ionis Pharmaceuticals stock for Q4 2024, down 11% quarter-over-quarter.
- 58 funds opened new Ionis Pharmaceuticals positions in Q4 2024 and 50 closed out, a net change of +8 holders.
- The largest Ionis Pharmaceuticals buyer in Q4 2024 was Capital World Investors, an estimated $136M added.
- The largest Ionis Pharmaceuticals seller in Q4 2024 was Artisan Partners, an estimated $74.3M sold.
Based on aggregated 13F filings for Q4 2024.